A5057541817- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Chromatin Remodeling and Cancer
- Cancer Treatment and Pharmacology
- Meningioma and schwannoma management
- Fibroblast Growth Factor Research
- Medical Imaging Techniques and Applications
- Sarcoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Neuroblastoma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer Research and Treatments
- Lung Cancer Research Studies
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Computational Drug Discovery Methods
- Mathematical Biology Tumor Growth
- Ocular Oncology and Treatments
- Nuclear Structure and Function
- Colorectal Cancer Treatments and Studies
- Bioinformatics and Genomic Networks
Columbia University
2016-2025
Penn Presbyterian Medical Center
2025
NewYork–Presbyterian Hospital
2006-2024
Columbia University Irving Medical Center
2015-2024
Herbert Irving Comprehensive Cancer Center
2014-2024
New York Hospital Queens
2006-2024
Presbyterian Hospital
2020-2024
Memorial Sloan Kettering Cancer Center
2010-2023
Baptist Health South Florida
2021
James J. Peters VA Medical Center
2021
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements computed tomography (CT) or magnetic resonance imaging (MRI), conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there significant limitations these criteria, which only address contrast-enhancing component of tumor. For example, chemoradiotherapy newly diagnosed glioblastomas...
Erlotinib is effective for epidermal growth factor receptor (EGFR) mutant lung cancer, but CNS penetration at standard daily dosing limited. We previously reported that intermittent "pulsatile" administration of high-dose (1500 mg) erlotinib once weekly was tolerable and achieved concentrations in cerebrospinal fluid exceeding the half maximal inhibitory concentration EGFR cancer cells a patient with leptomeningeal metastases; we now expand this paradigm to series 9 patients. retrospectively...
Abstract Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EC display addiction. In contrast KD mutants found cancer, glioma-specific are inhibited by inhibitors target active conformation (e.g., erlotinib). Inhibitors bind inactive conformation,...
Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, outcome further therapy after bevacizumab failure have not studied systematically.We identified patients at Memorial Sloan-Kettering Cancer Center with GBM who discontinued because progressive disease.There were 37 (26 men a median age 54 years). The most common therapies administered concurrently irinotecan (43%) hypofractionated...
Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or anaplastic (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for MG was progression-free survival at 6 months (PFS-6) overall 12 NP post-RT. Secondary objectives MGs response, survival, assessment of toxicity, pharmacokinetics (PKs). Treatment enzyme-inducing antiepileptic drugs not allowed. received 150 mg/day erlotinib. requiring surgery treated 7 days prior to...
No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) platelet-derived receptor, abundant in meningiomas.This was prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with recurrent World Health Organization (WHO) grades II-III meningioma. An exploratory WHO...
PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade (RANO-LGG) were developed to improve reliability of response assessment glioma trials. Over time, some limitations these identified, challenges emerged regarding integrating features the modified RANO (mRANO) or immunotherapy (iRANO) criteria. METHODS Informed by data from studies evaluating different criteria, updates are proposed (RANO 2.0). RESULTS We recommend a standard set...
Abstract Background Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised a monoclonal antibody that binds activated EGFR (overexpressed wild-type EGFRvIII-mutant) linked to microtubule-inhibitor toxin in EGFR-amp GBMs. Methods In this phase III trial, adults with centrally confirmed,...
Abstract Purpose: We investigated the molecular effect of epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated North American Brain Tumor Consortium trials 01-03 00-01 for recurrent or progressive malignant glioma. Experimental Design: EGFR expression signaling during treatment with were analyzed by Western blot compared pre–erlotinib/gefitinib–exposed tissue unexposed controls. Tumors also mutations other genomic...
Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), recombinantly produced fusion protein that scavenges both VEGF and placental in malignant glioma.Forty-two glioblastoma 16 anaplastic glioma who had received concurrent radiation temozolomide adjuvant were enrolled at first relapse. Aflibercept 4 mg/kg was administered...
Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms resistance, or both. The goal this randomized phase II study was to evaluate two different regimens adjuvant treatment GBM.Adult GBM were randomly assigned receive standard radiotherapy concurrent daily followed six cycles either dose-dense (150 mg/m(2) days 1 7 and 15 21) metronomic (50 continuous daily)...
Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram estimate survival probabilities patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Group (RTOG) clinical trials.This analysis included information on 799 (RTOG 0525) 555 0825) eligible randomized GBM contained following variables: age at diagnosis,...
We conducted a phase II trial to evaluate the efficacy of dasatinib, multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). Eligibility requirements were Karnofsky performance status ≥60%; no concurrent hepatic enzyme-inducing anticonvulsants; prior treatment surgery, radiotherapy, and temozolomide exclusively; activation or overexpression ≥2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2, PDGFR). Using 2-stage design, 77 eligible participants (27...
Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, an antibody-drug conjugate that preferentially binds cells EGFR amplification, internalized and releases potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, efficacy depatux-m monotherapy at recommended Phase 2 dose...